自然杀伤细胞联合他莫昔芬对乳腺癌细胞的杀伤作用及其机制

doi:10.13481/j.1671-587x.20170214

摘要/Abstract

摘要： 目的：通过体外实验观察自然杀伤细胞（NK细胞）联合他莫昔芬（TAM）对乳腺癌细胞（BCC）的协同杀伤作用，初步探讨其作用机制。方法：选用3种受体表达程度不同的BCC，设置空白对照组及TAM各浓度/时间梯度实验组，MTT法检测各组细胞增殖抑制率，并确定最终实验浓度为5 μmol·L^-1。设自然释放组、最大释放组、TAM组、NK细胞组和联合实验组（BCC+NK细胞+TAM），钙黄绿素-AM释放法观察不同效靶比下两者的联合杀伤作用。设空白对照组（NK细胞）、NK细胞+TAM组、NK细胞+BCC组和联合实验组，ELISA法检测各组NK细胞中TNF-α和IFN-γ水平。设空白对照组（NK细胞）、NK细胞+TAM组、NK细胞+BCC组和联合实验组，流式分析法分别检测NK活化性受体（NKp46）、NK抑制性受体（CD158a、CD158b、CD158b2和CD158e）表达水平。设空白对照组（BCC）、BCC+TAM组、BCC+NK细胞组和联合实验组，流式细胞术检测各组细胞中活化性配体（MICA、ULBP1和ULBP2）的表达水平。结果：MTT法检测，TAM对3种BCC的增殖抑制率具有明显的时间和浓度依赖性（P<0.05）。钙黄绿素-AM释放法检测，随着效靶比的增加，与NK细胞组比较TAM组BCC杀伤率明显升高（P<0.01），且联合组杀伤率明显高于NK细胞组和TAM组（P<0.05）。ELISA法检测，与空白对照组比较，各实验组无论有无BCC存在，NK细胞中分泌TFN-α和IFN-γ水平均升高（P<0.05或P<0.01），且与TAM联合后TFN-α和IFN-γ水平明显升高（P<0.05）。流式细胞术检测，与空白对照组比较，各实验组NK细胞中NKp46表达水平均升高（P<0.05）；各实验组NK细胞中CD158a、CD158b、CD158b2和CD158e表达水平均明显下降（P<0.05）；各实验组BCC中MICA、ULBP1和ULBP2表达水平均明显升高（P<0.05）。结论：NK细胞与TAM联合体外杀伤BCC具有协同作用，其协同作用机制可能为TAM能够通过促进NK细胞分泌 TNF-α和IFN-γ而增强其杀伤能力；通过增加NK细胞活化性受体和活化性配体表达水平、降低NK细胞抑制性受体表达水平，进而增加NK细胞的杀伤能力。

关键词: 免疫治疗, 乳腺肿瘤, 他莫昔芬, 内分泌治疗

Abstract: Objective: To investigate the synergistic killer effect of natural killer cells(NK cells) combined with tamoxifen(TAM) on breast cancer cells(BCC)through the experiment in vitro,and to explore its mechanism. Methods: Three kinds of BCC with different receptor expression levels were selected for the experiment. Blank control group, different concentrations of TAM groups and different time groups were setup.MTT assay was used to detect the inhibitory rates of proliferation of cells,and the final experiment concentration of 5 μmol·L^-1 was determined.The cells were divided into natural-release group,largest-release group,TAM group,NK cells group, and combined-experimental group(BCC+NK cells+TAM),and the synergistic killer effect of NK cells combined with TAM in different effector-target ratios were detected with Calcein-AM release assay.In ELISA assay the cells were divided into blank control group (NK cells),NK cells+TAM group, NK cells+BCC group and combined-experimental group,and the levels of IFN-γ and TNF-α in the NK cells in various groups were measured.In flow cytometry detection the cells were divided into blank control group (NK cells),NK cells+TAM group,NK cells+ BCC group, and combined-experimental group,and the expression levels of NKp46,CD158a,CD158b,CD158b2,and CD158e were determined;while the cells were divided into blank control group (BCC),BCC+TAM group,BCC + NK cells group, and combined-experimental group,and the expression levels of the MICA,ULBP1 and ULBP2 were detected. Results: The MTT assay results showed that the inhibitory rates of proliferation of 3 kinds of BCC had obvious time- and concentration-dependence (P<0.05).The Calcein-AM release assay results showed that the killing-rates of BCC in TAM groups were increased with the increase effector-target ratios of compared with NK cells group;and the killing-rate in combined experimental group was obviously higher than those in NK cells and TAM groups(P<0.05).The ELISA assay results showed that the levels of TNF-α and IFN-γ of NK cells in various experimental groups with BCC or not were increased compared with blank control group(P<0.05 or P<0.01);the levels were significantly increased when combined with TAM (P<0.05).The flow cytometry results showed that the NKp46 expression levels in various experimental groups were elevated compared with blank control group(P<0.05);the expression levels of CD158a, CD158b,CD158b2, and CD158e were significantly decreased(P<0.05);the expression levels MICA,ULBP1, and ULBP2 in BCC were significantly increased (P<0.05). Conclusion: The NK cells combined with TAM has the synergistic killer effect on the BCC in vitro.The synergetic mechanism may be as follows:TAM could increase the secretion of TNF-α and IFN-γ of NK cells to enhance their cytotoxicity;TAM also could up-regulate the expression levels of activating receptors and activating ligands,and down-regulate the expression levels of inhibitory receptors to increase the killing ability of NK cells.

Key words: tamoxifen, endocrine therapy, breast neoplasms, immunotherapy

中图分类号:

R733.6

王迦南, 冯辉, 王倩, 何悦铭, 宋艳秋, 朱继红. 自然杀伤细胞联合他莫昔芬对乳腺癌细胞的杀伤作用及其机制[J]. 吉林大学学报(医学版), 2017, 43(02): 281-287.

WANG Jianan, FENG Hui, WANG Qian, HE Yueming, SONG Yanqiu, ZHU Jihong. Killer effect of natural killer cells combined with tamoxifen on breast cancer cells in vitro and its mechanism[J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 281-287.

参考文献

[1] Igene H.Global health inequalities and breast cancer:an impending public health problem for developing countries[J].Breast J,2008,14(5):428-434.
[2] Onitilo AA,Engel JM,Greenlee RT.Breast cancer subtypes based on ER/PR and Her2 expression:comparison of clinicopathologic features and survival[J].Clin Med Res,2009,7(1/2):4-13.
[3] Milani A,Geuna E,Mittica G,et al.Overcoming endoccrine resistance in metastatic breast cancer:Current evidence and future directions[J].World J Clin Oncol,2014,5(5):990-1001.
[4] Patel RR,Sharma CG,Jordan VC.Optimizing the antihormonal treatment and prevention of breast cancer[J].Breast Cancer,2007,14(2):113-122.
[5] 张厚云,赵凌云.乳腺癌内分泌治疗研究进展[J].中国普通外科杂志,2014,23(5):680-684.
[6] 朱歌.曲妥珠单抗联合NK细胞对乳腺癌细胞体外杀伤作用的实验研究[D].长春:吉林大学,2014.
[7] 董营.表柔比星序贯NK细胞体外杀伤乳腺癌细胞的研究[D].长春:吉林大学,2015.
[8] Feng H,Dong Y,Wu J,et al.Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitro [J].Am J Translat Res,2016,8(2):473.
[9] Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[10] Pagani O,Regan MM,Francis PA.Are SOFT and TEXT results practice changing and how?[J].Breast,2016,27:122-125.
[11] Salami S,Karami-Tehrani F.Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines[J].Clin Biochem,2003,36(4):247-253.
[12] Metah A, Tripathy D.Co-targeting estrogen receptor and HER2 pathways in breast cancer[J].Breast,2014,23(1):2-9.
[13] Musgrove EA,Sutherland RL.Biological determinants of endocrine resistance in breast cancer[J].Nat Rev Cancer,2009,9(9):631-643.
[14] Ellis MJ,Coop A,Singh B,et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive,estrogen receptor-positive primary breast cancer:evidence from a phase Ⅲ randomized trial[J].J Clin Oncol,2001,19(18):3808-3816.
[15] Ellis MJ,Tao Y,Young O,et al.Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole[J].J Clin Oncol,2006,24(19):3019-3025.
[16] Lanier LL.NK cell recognition[J].Annu Rev Immunol,2005,23:225-274.
[17] 王鹏,李玲,阚全程,等.表达US3基因腺病毒载体下调CTL和NK细胞对其转染肝细胞杀伤活性的影响[J].西安交通大学学报:医学版,2015,36(5):655-660.
[18] 吴朝真,刘放,李宁.Fractalkine、IP-10及不同信号通路抑制剂对肿瘤微环境中NK细胞的影响[J].解放军医学杂志,2015,40(7):547-553.
[19] Wang W,Erbe AK,Hank JA,et al.NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy[J].Front Immunol,2015,6:368.
[20] 闫振北,韩明强.雌激素水平影响他莫昔芬抑制乳腺癌细胞生长的机制探讨[J].中国医刊,2008,43(1):57-58.
[21] Chang E,Rosenberg SA.Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy[J].J Immunother,2001,24(1):88-90.
[22] 高德宗,孙靖中,高华,等.γ-干扰素增强他莫昔芬抗乳腺癌作用的体外研究[J].中国肿瘤生物治疗杂志,2006,13(1):45-49.
[23] 张巧利,李芬,吕淑兰,等.乳腺密度、性激素补充治疗与乳腺癌的关系[J].中国老年学杂志,2015,35(17):5012-5016.